Clarke DK, Xu R, Matassov D, Latham TE, et al. Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial. Lancet Infect Dis 2020 Jan 14. pii: S1473-3099(19)30614.
PMID: 31952923